GSK: FIRST SINGLE-DOSE MEDICINE TO PREVENT RELAPSE OF P. VIVAX MALARIA LAUNCHED IN THAILAND AND BRAZIL
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,329.50 GBX | -0.34% | -0.89% | -8.32% |
05:18pm | GSK's Endometrial Cancer Drug Jemperli Secures EU Panel's Positive Opinion for Label Expansion | MT |
Dec. 11 | GSK : Goldman Sachs reaffirms its Neutral rating | ZD |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,329.50GBX | -0.34% | -0.89% | 69.14B | ||
6.3491BRL | +1.18% | -1.35% | - | ||
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
- News GSK plc
- Gsk: First Single-Dose Medicine To Prevent Relapse Of P. Vivax M…